Introduction
The spread of cancer to nearby and distant sites involves a series of steps known as the metastatic cascade: local invasion, entrance into the vasculature (intravasation), exit from the vasculature (extravasation), and growth in a distant tissue [1, 2] . Despite advances in our understanding of cancer progression, key steps in the metastatic process are still poorly understood and seldom observed directly in vivo. We have now begun to understand the gene expression and biochemical changes that accompany tumor progression. However, our understanding of the basic cell biology of metastasis will remain incomplete until we can image molecular events within tumors. To accomplish this, advanced techniques are needed to visualize tumor cells in their relevant environments so as to capture their behavior and the molecular changes taking place as they navigate through the different stages of metastasis.
Advanced imaging approaches are not only important for understanding the biology of metastasis on a fundamental level but also are likely to impact upon patient outcome. Timely detection and accurate staging of human cancer is crucial because the course of treatment selected depends directly on the location and pathological characterization of the tumor mass. Therefore, methods to accurately detect early stage cancer, and reliably diagnose and stage progressing cancers, can have a profound impact on treatment courses that can increase patient survival. In particular, there is a clear requirement for imaging techniques that can distinguish early hyperplastic lesions from normal tissue and malignant versus benign tumors. Optical techniques that can identify changes in cellular behavior and/or the extracellular matrix (ECM) to produce consistent and quantifiable markers of cellular and molecular changes associated with cancer, or 'optical biomarkers', are therefore to be desired. Such optical biomarkers, when linked to molecular pathways, have the potential to provide guidance for specifically targeted therapeutic intervention. Several recent advances in the optical imaging of tumor progression, reviewed here, are beginning to make this potential achievable.
The need to see cancer at the cellular scale At present, most clinical tools focus on identifying a tumor mass that is large enough to be detected with whole body/ organ imaging technologies, including ultrasound, magnetic resonance imaging, computed tomography, fluorescence-mediated tomography, and positron emission tomography (PET) [3, 4] . PET in particular has promise due to its ability to selectively image tumors based on metabolism, proliferation, or specifically labeled receptor or antigen biomarkers [5] . Yet, while these tools are extremely valuable in clinical oncology, and are the primary means for non-invasively detecting a tumor mass, they are not capable of subcellular resolution [3, [5] [6] [7] . For this reason they are unlikely to provide a highly accurate indication of disease state because a comprehensive understanding of cancer progression requires the visualization of single-cell phenotypes linked to defined molecular pathways. Therefore a great deal of work has been directed towards the imaging of single cells and the identification of optical biomarkers that are reliably indicative of early cell transformation, such as changes in cell metabolism [8] [9] [10] [11] [12] [13] [14] or in the architecture of the stromal ECM microenvironment [8, 12, 13, 15, 16] . However, at the time of detection, it is common for tumors to have already progressed to an invasive stage. As such, any information that helps to halt or limit the spread of primary tumor cells to new sites in the body, or indicates treatment for secondary tumor risk, is clearly of importance. Yet, detecting optical biomarkers that specify an invasive tumor is more complex than tumor mass detection. Moreover, in order for optical biomarkers associated with metastasis to reach their full potential, detailed understanding will be required of their coupled molecular mechanisms in the context of the cell phenotype, initially in animal studies, and ultimately in patients.
Multiphoton laser-scanning microscopy (MPLSM) has provided recent insights into the mechanisms underlying cell motility events and has fostered the characterization of optical biomarkers associated with metastatic processes. The technique allows visualization of invasive cells within 3D microenvironments in vivo and in vitro. Here, we highlight these novel findings obtained from MPLSM imaging of cancerous cells within their native environments, with particular emphasis being placed on the potential to link molecular mechanisms of motility during local invasion through the collagenous stroma with optical biomarkers indicative of disease state. Current limitations of optical imaging as a diagnostic tool mean that emerging technologies will increase the diagnostic potential of MPLSM.
Of course, while MPLSM provides particular advantages over many of the more conventional optical-imaging technologies, and is uniquely suited for high resolution imaging of the collagen matrix, it is important to note that recent advances in other imaging modalities -such as optical coherence tomography [17] [18] [19] , spinning disk confocal microscopy [20, 21] , and photoacoustic tomography [22, 23] -are also capable of providing insights into the behavior of single cancer cells. However, discussion of these imaging modalities is beyond the scope of the current review and the reader is encouraged to examine the listed references for additional information. Moreover, because technologies such as these can often be combined with MPLSM for multimodal imaging approaches (e.g. Refs. [17, 24] ) they can provide an even greater depth of information to aid our understanding of tumor biology.
Nonlinear optical imaging for cell biology Multiphoton laser-scanning microscopy is an optical sectioning technique where the fluorescence emission is proportional to the molecular cross-section and has a quadratic dependence on the excitation laser power [25] [26] [27] (Box 1; for detailed reviews of MPLSM and second harmonic generation see Refs. [7, [27] [28] [29] [30] ). Due to this quadratic dependence on excitation intensity, higher-order processes are unlikely to occur outside the focal volume (i.e. the probability of two or more photons simultaneously exciting a fluorophore outside the focal volume is extremely low) [26] . As a result, improved signal-to-noise and background discrimination is achieved without the need for a confocal aperture, and this allows the majority of emitted photons to be collected while not photobleaching the out-offocus volumes of the tissue. Moreover, mode-locked lasers used for MPLSM excite at longer wavelengths than conventional fluorescence imaging (they typically excite in the 650-1050 nm range; this broad tunability also has practical advantages as it allows excitation of a wide range of fluorophores). Longer wavelengths permit deeper penetration into tissues because they are more immune to light scattering, and MPLSM also allows more efficient collection of scattered photons emitted during deep tissue imaging. In addition, the use of pulsed lasers reduces photodamage because the mean power at the sample is minimized. The viability of many cells and tissues is also improved when longer wavelengths are used because these Box 1. Multiphoton laser-scanning microscopy (MPLSM)
Multiphoton microscopy possesses several advantages over more conventional microscopy techniques for imaging cells within 3D matrices.
Short pulses of longer wavelength light (typically 650-1050 nm) are used such that two or more photons (i.e. twice the normal, singlephoton, excitation wavelength for 2-photon excitation) are absorbed to excite a fluorophore, resulting in reduced scattering and permitting much deeper tissue imaging [26, 33] . The longer excitation wavelength does not decrease resolution versus other optical imaging techniques [102] . Excitation remains restricted to the plane of focus (optical sectioning) because the probability that two or more photons simultaneously excite a fluorophore outside the focal volume is extremely low [26, 27] . Therefore, an aperture (used with confocal microscopy, Refs. [103] [104] [105] ) to reduce out-of-plane fluorescence is not needed, permitting a much greater emission signal collection efficiency as well as non-descanned (direct) detection to capture more light, particularly during deep tissue imaging [7, 106] . The pulsed lasers used with multiphoton microscopy use a high peak-power (that also significantly enhances the signal, Ref. [29] ), but the average power delivered to the sample is modest because the excitation is not continuous; the long wavelengths used have been shown to be less damaging to tissue. When combined with the lack of fluorescence excitation outside the focal plane, MPLSM is significantly less phototoxic [32] ; this is very important for longterm cell biology studies, the imaging of precious live tissue biopsies, and when performing live-cell intravital imaging in vivo.
Another advantage of MPLSM is that it readily generates harmonic signals [107] that differ from fluorescence signals in that harmonic emission signal is coherent (e.g. 2-photon excitation at 900 nm for second harmonic generation, SHG, results in a perfect 450 nm emission signal). In theory, harmonic generation does not release energy into the sample [107] , and is therefore optically noninvasive, so allowing long-term imaging of biological structures. Strong harmonophores relevant to cell biology are based on biomolecule arrangement and structure; these include fibrillar collagen [48] [49] [50] [51] [52] , myosin, and tubulin [30, 48, 53] . Harmonic signals from these proteins can be separated easily from fluorescent signals with standard filtering technologies as well as by measurements of fluorophore lifetime (harmonic signals do not undergo fluorescence intensity decay over time). Emission signals from multiphoton excitation can be used to determine changes in fluorescence anisotropy or lifetime; these indicate changes in molecular conformation, biochemical microenvironment, and binding state [108] . Moreover, fluorescencelifetime imaging microscopy (FLIM [109, 110] ) is particularly useful for fluorescence resonance energy transfer (FRET) experiments as a change in donor or acceptor fluorescence lifetime can be used to indicate FRET independently of the molar concentration of each fluorophore [111] [112] [113] . Fluorescence-lifetime analysis of multiphoton emission signals allows acquisition of fundamental signaling information in cells within 3D microenvironments in vitro or in vivo.
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Trends in Cell Biology Vol. 19 No.11 circumvent some of the known mechanisms of phototoxicity (e.g. UV-sensitive cell-cycle checkpoints) [31, 32] . Hence, MPLSM [26] can image deeper [26, 33] into 3D structures, with improved signal-to-noise ratios [26, 29, 33] and viability [32] , than more conventional optical imaging techniques such as confocal microscopy [33] . It should be noted, however, that the discussion of deep tissue imaging is in the context of optical imaging, where MPLSM provides an effective imaging depth that greatly exceeds that of conventional optical imaging approaches, but is still significantly less than current clinical tools that can image through the human body. Standard MPLSM can image effectively to depths of 400-1000 mm, depending on the tissue structure [25, 29] , and though this currently precludes imaging through the skin into human organs, it does not exclude MPLSM as a potential diagnostic tool (see Box 2) or its utility for studying fundamental cell biology. With MPLSM, cell biology studies can now be performed on cells within relevant 3D matrices [34] [35] [36] as well as in vivo with intravital imaging [37] [38] [39] [40] . This allows detailed analysis of cell phenotype, and a quantitative description of cell behavior (migration speed, direction) within biologically relevant environments. Moreover, MPLSM is particularly well-suited to image quantum dots or cells expressing fluorescent protein(s) (whereas a detailed discussion of fluorescent proteins and biosensors is beyond the scope of this review, the reader is encouraged to examine recent reviews describing this rapidly growing and exciting field; in particular Refs. [41] [42] [43] [44] [45] [46] [47] and Lidke and Wilson in this issue). Fluorescent protein technologies for localization studies, and multiple fluorescent labels for protein-protein interaction/activation studies with Förster resonance energy transfer (FRET) [42] [43] [44] , are providing novel insights into signal transduction in vivo (see review by Balla, this issue).
MPLSM is additionally advantageous because it generates harmonic signals; these are not fluorescence-based but are instead a polarization process with an emission wavelength equal to exactly half of the excitation wavelength [48] [49] [50] [51] , and can therefore be easily separated from the fluorescence signals. In the context of cell biology, this results in second and third harmonic generation (SHG and THG, respectively) signals from biological components, such as fibrillar collagen [48] [49] [50] [51] [52] , myosin, and tubulin [30, 48, 53] . This proves to be a very useful aspect because biological materials such as collagen are strong harmonophores, and this provides a powerful means for the simultaneous imaging of collagen and selected fluorophores. The approach thus allows imaging of cells (and relevant intracellular components) within complex 3D collagen matrices, and therefore permits molecular pathways representative of the in vivo condition to be defined, and can also provide ECM diagnostic markers linked to tumor progression [15, 34] .
Imaging tumor cell motility in 3D microenvironments in vivo and in vitro Multiphoton laser-scanning microscopy has been used to study cancer cell motility and local invasion in vivo and within 3D microenvironments in vitro to provide novel information about these processes. Although the following is not a comprehensive review of the regulation of these processes in metastasis, the studies presented here have established correlations between particular cell phenotypes and molecular pathways, providing a potential link between the fundamental cell biology and optical biomarkers.
Tumor cell phenotypes during local invasion and intravasation Three primary cell phenotypes have been reported for cells migrating through the ECM during local invasion: (i) amoeboid, (ii) mesenchymal (also referred to as fibroblastoid), and, (iii) collective migration, depending on tumor type, stage, and location relative to the primary tumor mass or vasculature ( Figure 1 ). Fundamental work by Condeelis and colleagues [54] used intravital multiphoton microscopy to identify key differences between welldescribed motility phenotypes on 2D substrates and the mechanisms of cell motility during metastasis in vivo. Notably, they observed that migrating cancer cells moved along collagen fibers towards and into blood vessels with rapid shape changes and no cell polarity, characterized as amoeboid motility [37, 54] , which is distinct from fibroblasttype migration where cells are elongated and form a welldefined lamellapodia [37] . Furthermore, MPLSM imaging of live tumors and carcinoma cells in 3D culture show
Box 2. Diagnostic potential of MPLSM
Although MPLSM has emerged as a powerful technology to study cell phenotype and associated signal transduction in 3D microenvironments, the clinical capability of MPLSM currently remains limited because the imaging depth is still not adequate for deep organ imaging through the skin. Even so, MPLSM still holds great promise as a diagnostic technology.
Current work is focusing on imaging both live tissue tumor biopsies and stained and unstained histology slides as a way to obtain additional quantitative information to supplement standard histopathology [8, 11, 12, 15, 114, 115] . Rapid imaging of live tumor biopsies or resected tumors immediately following harvest could permit initial diagnostic evaluation before standard tissue processing for histology. Samples can then be examined further for quantitative metrics to assist the pathological assessment. MPLSM has potential as a diagnostic tool in vivo through multiphoton fluorescence endoscopy [116] [117] [118] [119] [120] with sub-cellular resolution [118, 120] , or by imaging skin directly [121] . Recent advances in microlenses may further extend the applicability of these approaches [122, 123] . In particular, gradient refractive index (GRIN) lenses, that can be several centimeters in length and 1-2 mm in diameter, hold particular promise for extending in vivo imaging with MPLSM [120, 122, 123] . MPLSM has been used for the efficient detection of circulating tumor cells in the small vessels of the peripheral vasculature with multiphoton intravital flow cytometry [124] . If this technology can be effectively coupled with fluorescent markers of circulating tumor cells, or with other markers of cancerous cells in the vasculature, it could hold great potential for the detection of circulating tumor cells through thin regions of skin in human patients.
Ongoing advances in adaptive optics [125] are likely to increase the effective imaging depth of MPLSM by correcting for aberrations due to refractive index inhomogeneities within tissues [125] [126] [127] [128] . Correction for such aberrations will greatly increase the effective imaging depth for MPLSM. When combined with the technologies discussed above, MPLSM could prove to be a very effective tool for imaging thick extracted tumor specimens and for in vivo imaging in human patients.
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features of collective invasion (sheets, strands, and tubes) in regions of local invasion, as well as single-cell mesenchymal and amoeboid phenotypes, in contact with aligned collagen fibers [8, 15, 34, 36, [55] [56] [57] [58] . Each of these phenotypes has been linked to the regulation of specific signaltransduction networks. A brief description of these findings follows.
Elucidating the influence of extracellular proteases with MPLSM Interestingly, amoeboid motility phenotypes were also identified during in vitro migration within 3D matrices in a protease-dependent manner [56, 59] . In 3D collagen matrices, broad inhibition of multiple protease families results in a switch from mesenchymal motility, characterized by strong b1-integrin localization at the cell-matrix interface [56, 60] co-localized with active MT1-MMP (MMP14) [56] , to an effective amoeboid-like migrationtermed a mesenchymal-amoeboid transition [56] . Intravital multiphoton microscopy of fibrosarcoma cells treated with protease inhibitors and then injected into the mouse dermis supports the conclusions of in vitro 3D matrix experiments, suggesting a mechanism for protease-independent amoeboid movement in vivo [56] . Moreover, MPLSM imaging of collagen fibrils in reconstituted collagen 3D matrices demonstrated that broad protease inhibition did not inhibit the ability of the cell to reorganize the matrix or invade into the matrix [34, 36] . However, it is generally accepted that in vivo, before invasive cells can break free of the primary tumor mass and invade into the stroma, the physical ECM boundary at the tumor-stroma interface must be broken down and/or reorganized [61, 62] . A need for protease activity in vivo makes intuitive sense when one observes the tumor boundary using SHG imaging -this has revealed that non-invasive regions of tumors are confined by collagen fibers arranged parallel to the tumor boundary [8, 15] (also providing an optical biomarker for use when inspecting for the presence or absence of local invasion; see Box 3 and Figure 2 ). Thus, while multiple studies have presented strong evidence demonstrating that tumor cells can migrate through the collagen matrix in the absence of protease activity [34, 36, 56, 59 ], most of this work has been performed in 3D culture in vitro or on cells injected into mouse models.
In vivo there is a defined matrix architecture that results from normal development; this becomes stretched by the growing tumor and is later reorganized and aligned, so facilitating local invasion into the stroma [15] . In live tumors, MPLSM imaging reveals that this transition occurs over time (weeks to months in rapidly progressing mouse tumor models; this could indicate changes taking place over months to years in human patients). It therefore seems likely that remodeling of the collagen matrix might be required [61, 63, 64] to aid a matrix re-alignment that facilitates invasion. Moreover, recent work by Sabeh and co-workers [61] suggests that part of the discrepancy between protease-dependent and protease-independent 3D migration may be influenced by the preparation of the collagen matrix; in particular, whether or not the ECM is crosslinked, and whether or not a path for the cell has already been created [55, 61, 65] , suggesting that more work needs to be performed in native environments in vivo. Combined, these reports advocate that studies to understand proteolytic degradation of the ECM in vivo will require real-time imaging of single cells at the invasion boundary of endogenous tumors, along with tumor-associated cells of the microenvironment, and of the collagen fibers adjacent to the invading cells. However, in vivo studies also provide strong evidence that an amoeboid phenotype exists in tumors [36, 37, 54, 56] , and suggests that the invading cells may not be susceptible to protease inhibition. The detection of amoeboid phenotypes in biopsy sections may therefore guide decisions regarding the therapeutic regime.
Molecular pathways that regulate motility: therapeutic targets? Sahai and co-workers identified a link between the mechanism for migration through 3D matrices and the Rho/ ROCK signaling pathway [59] . In rounded, dynamically blebbing cells analogous to amoeboid phenotypes, blockade of Rho/ROCK signaling is significantly more effective at reducing 3D migration than in cell lines with elongated phenotypes [59] . Knockdown of Smurf1, a ubiquitin ligase that can target RhoA for degradation, increases RhoA activity and promotes tumor cell motility through a mesenchymal-amoeboid transition [66] , suggesting that in contrast to protease therapy, cells with amoeboid phenotypes may be susceptible to targeted inhibition of the Rho pathway. Importantly, using MPLSM it was recently The presence or absence of these phenotypes largely depends on tumor type, the state of the stromal ECM, and the cellular composition of the microenvironment. Collective migration (1), where cells remain physically connected to each other and have a multicellular polarity [58] , can present as sheets of cells with a leading edge, lines of cells or groups of cells, or as a collective group that has detached from the primary tumor. These groups of tumor cells have focal 3D matrix adhesions, generate traction force, and have an active proteolytic program to modify the ECM. Amoeboid motility (2a) is characterized by a rounded or ellipsoid morphology, a lack of cell polarity, and non-focal 3D matrix adhesions that facilitate high-velocity movement through the matrix. Mesenchymal migration (2b) is distinguished by an elongated morphology, focal 3D matrix adhesions and an active proteolytic program. Each of these phenotypes is regulated by unique molecular programs. Furthermore, it is clear that invasive cells have multiple compensatory mechanisms to switch between these phenotypes so as to migrate efficiently through collagenous matrices. For in-depth discussion of these phenotypes readers are encouraged to examine Refs. [37, 58, 137] .
Trends in Cell Biology Vol.19 No.11 established that Rho/ROCK signaling and the consequent acto-myosin regulated contractile force are necessary for local collagen matrix deformation/reorganization near the cell boundary [34, 36] . This matrix reorganization near the cell boundary provides physical contact guidance cues that strongly influence cell migration through 3D matrices [34, 67, 68] . Interestingly, when the collagen matrix is engineered to mimic the matrix architecture that most efficiently promotes 3D migration, Rho and ROCK become unnecessary for the migration of invasive breast carcinoma cells through the collagen matrix [34] ; this finding suggests that the role of the Rho-mediated intracellular contractile force during 3D migration could be more related to organizing the microenvironment than to regulating the movement of single motile cells.
In regions of local invasion, MPLSM imaging has revealed that collective invasion takes place at regions of matrix re-alignment together with single motile cells progressing deep into the aligned stroma [8, 15, 34] . This may be especially true for a subpopulation of individual tumor cells that may migrate particularly fast if they have been strongly stimulated by paracrine signaling from tumor-associated macrophages [37, [69] [70] [71] , are exposed to an ECM architecture that promotes migration, or are subject to paracrine stimulation by tumor-associated fibroblasts [65, 72] . Chemotactic gradients can enhance the invasion process by stimulating intracellular signaling networks associated with cell motility. Microarray analysis of invasive MTLn3 rat adenocarcinoma cells in vivo (compared to the non-metastatic MTC cell line), that were previously used to identify amoeboid movement with MPLSM for cells migrating along collagen toward blood vessels [54] , identified the growth factor (EGF and CSF-1)-regulated 'minimum motility pathway' [54, 73, 74] . This pathway is characterized by regulation of the actin cytoskeleton and in particular by three end-stage effectors -the Arp2/3 complex, capping protein, and cofilinthat influence actin dynamics associated with cell motility [73, 75, 76] , and directly link an in vivo cell phenotype identified by MPLSM with molecular targets. Furthermore, Mena, an Ena/Vasp protein that antagonizes actin capping, is upregulated [54, 73, 74] , and intravital multiphoton imaging experiments showed that cells overexpressing EGFPMena in orthotopic xenografts are more motile [77] . Interestingly an isoform of Mena (termed Mena INV ) enhances sensitivity to EGF stimulation and promotes EGF-induced cell motility and invasion, suggesting that these cells are more likely to metastasize even in the presence of basal levels of EGF [77] . Hence, it is clear that invasive cells have multiple compensatory mechanisms to migrate efficiently through collagenous matrices, highlighting the need for a detailed understanding of the link between cell phenotype and active signal transduction in the identification of cell populations that may or may not be susceptible to a particular therapeutic intervention.
The need to image 3D-matrix adhesions in vivo
In addition to chemoattraction, integrin-mediated adhesion is known to play a role in tumor progression to Box 
Optical biomarkers
Optical biomarkers are changes in cellular behavior, phenotype, or physico-chemical properties, and/or changes in extracellular matrix composition and architecture, that are detectable by optical imaging technologies. These cancer-associated cellular and molecular changes can be consistently quantified and have great diagnostic potential.
Metabolic markers
Due to changes in metabolic state associated with increased glycolysis in tumors, the detection of changes in fluorescence intensity and/or fluorescence lifetime of metabolic intermediates such as NADH and FAD, and their redox ratios, can provide information indicating cellular transformation or the presence of subpopulations of tumor cells with metastatic potential [8] [9] [10] [11] [12] [13] .
Stromal collagen markers
Although collagen deposition surrounding tumors has long been noted by pathologists, the functional significance of desmoplasia and collagen architecture has been investigated in vivo only recently. Significant changes in the collagen matrix occur with tumor initiation and progression, and these can be used as optical biomarkers.
Tumor-associated collagen signatures (TACS) [8, 15] . To date three TACS have been defined related to collagen architecture:
-TACS-1: locally dense collagen within the global increase of collagen concentration surrounding tumors, and is identified by increased signal intensity at a region near the tumor; this can serve as a reliable hallmark for locating small tumor regions. -TACS-2: straightened collagen fibers stretched around the tumor (i.e. tumor expansion that strains the fibers resulting in the loss of the wavy collagen crimp pattern). The collagen is organized parallel to the tumor boundary and is associated with non-invasive regions of the tumor mass.
-TACS-3: collagen that has been re-organized so that it is radially aligned (perpendicular) to the tumor-stroma boundary and is characteristic of regions of local invasion.
Changes in collagen structure due to degradation (resulting from extracellular protease activity), altered fibril composition, and/or defective collagen fibril formation and the associated changes in SHG signalscattering might also be indicative of changes in the stroma that point to tumor initiation or tumor progression. Because the SHG signal is sensitive to fibril organization and structure, changes in the scatter properties of the SHG signal can be used to determine changes in collagen structure. As an example, collagen structure is abnormal in connective tissue disorders such as osteogenesis imperfecta (OI). Dermis from a mouse model of OI demonstrates significant differences in forward/backward scatter of the collagen SHG signal compared to wildtype tissue [129] . Thus, quantitative analysis of scattering can be used as an optical biomarker, particularly because changes in collagen structure can influence cancer cell invasion [130] .
Intermolecular cross-links of collagen are fluorescent and can be imaged with MPLSM [131] . Tissue transglutaminase and lysyl oxidase, both of which cross-link collagen, are altered in tumors [132, 133] , and collagen crosslinking may influence cancer cell invasion [61] . Thus, autofluorescence signals from collagen cross-links can be readily detected with MPLSM and therefore represent another potential optical biomarker for tumor progression.
Additional optical biomarkers
Whereas collagen and the metabolites NADH and FAD are the bestcharacterized intrinsic fluorophores of relevance to cancer, there are many other intrinsic fluorophores that warrant further study in view of their potential in cancer research (and are perhaps future biomarkers); these include protoporphyrin IX [134, 135] (a component of the heme pathway), lipofuscin [91, 136] , elastin [91] , and tryptophan [91, 93] . 11 metastasis [78] . Matrix adhesions in motile cells in 3D environments are not well understood, largely due to a current lack of high-resolution imaging studies of these structures relative to the ECM microenvironment in vivo, and are probably less developed than the large focal adhesions that form on rigid 2D substrates. Current evidence strongly suggests a role for integrins and focal adhesion proteins in regulating metastasis-associated motility in vivo. For instance, focal adhesion kinase (FAK) is a welldescribed regulator of focal adhesion and cell motility [79] , is overexpressed in numerous human cancers [80] , and its loss has been shown to block malignant conversion [81, 82] . In addition, FAK has been shown to regulate invasion by influencing urokinase plasminogen activator (uPA) activity [83] , perhaps resulting in ECM changes detectable by MPLSM. Moreover, FAK deletion represses several transcripts associated with adhesion, motility, and the cytoskeleton (many of which are 'minimum motility pathway' genes identified by MPLSM imaging and the simultaneous collection of invasive cells in vivo; Refs. [54, 73] ). Optical biomarkers detected with MPLSM. Multiphoton microscopy allows the study of single cell behaviors relevant to metastasis in 3D microenvironments both in vitro and in vivo. MPLSM imaging of live tumor cells has not only provided new information about the cell biology of metastasis, but has also provided novel optical biomarkers that have diagnostic potential. For instance, changes in collagen matrix architecture, termed tumor-associated collagen signatures (TACS), help to distinguish invasive from non-invasive tumor regions (i.e. TACS-2 versus TACS-3). MPLSM micrographs (multiphoton excitation of endogenous fluorescence from FAD) are shown with simultaneous SHG of the collagen matrix in (i) live, intact, mammary gland, (ii) non-invasive regions of mammary tumor (TACS-2), and (iii) invasive regions of mammary tumor (TACS-3; See Box 3). As highlighted in the associated cartoons, the collagen fiber angle distributions associated with these matrix morphologies can be quantified (i.e. fiber angle distribution diagrams shown in the upper left corner), and used to quantitatively distinguish regions of invasion from non-invasive regions of the tumor. Furthermore, changes in cell metabolism associated with transformation and tumor progression can be detected in single tumor cells and provide an optical biomarker for disease state (e.g. the MPLSM-FLIM image of TACS-3 showing differences in the fluorescence lifetime of FAD in invading cells versus cells in the primary tumor mass; note the difference in heat-map color and intensity in cells in the stroma versus the primary tumor mass). When linked to defined signal-transduction pathways, optical biomarkers such as these may help to guide therapeutic intervention by indicating whether therapy targeted against a particular pathway is appropriate. Collagen is depicted in yellow and basement membrane in the normal gland is shown in light green. MPLSM and MPLSM-FLIM images are adapted and reproduced from Provenzano et al. [15] , with permission.
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Trends in Cell Biology Vol. 19 No.11 This suggests that FAK regulates actin dynamics and cell protrusion and motility [81] . In addition, FAK-null cells injected into the vasculature cannot efficiently form the protrusions across the vessel wall that are necessary for extravasation [84] . Hence, adhesion complexes and regulators of the actin cytoskeleton are emerging as viable targets for metastasis therapy. Even so, while FAK has been associated with regulating a subset of genes that are predictive of human patient outcome [81] , and a number of gene signatures have been compiled to predict patient outcome [85] [86] [87] [88] , specific quantitative information linking cell and/or matrix phenotype to specific cells bearing these signatures is currently lacking. Therefore, studies to identify optical biomarkers and signal transduction pathways/gene signatures within invading cells are of great value not only by increasing our basic understanding of tumor biology, but also by providing information that can be used in a diagnostic capacity to guide therapeutic intervention.
Optical biomarkers
In addition to exogenous fluorescent markers such as GFP and quantum dots used to track molecular events in cells, there is a set of 'built-in' endogenous fluorophores that can be exploited to further our understanding of normal and pathologic processes. These molecules have the advantage of being naturally present in cells and tissues of interest, are involved in key biological processes, and therefore can be imaged in live, unstained tissue. Not only are these endogenous fluorophores of great use in various cell culture and animal models, but will ultimately be of use as disease state biomarkers in human samples where fluorescentlabeled proteins are not available.
Metabolic intermediates
It has long been known that glycolysis is increased in tumors [89, 90] , and specific metabolic intermediates are emerging as intrinsic optical biomarkers of these changes. In particular, the metabolites nicotinamide adenine dinucleotide (NADH; reduced form) and flavin adenine dinucleotide (FAD; oxidized form) have characteristic fluorescent properties and spectral emissions [91] [92] [93] and are detectable in live, unstained cells [10, 11] . Moreover, changes in the redox state of the cell can be determined by imaging relative NADH and FAD intensities [12, 94] , and the ratio correlates linearly with glucose uptake in tumor models [95] .
In addition to intensity changes, fluorescent lifetime microscopy (FLIM, Box 1) can be exploited to detect changes in metabolic state that accompany tumor progression. The fluorescence lifetimes of protein-bound versus free NADH or of FAD differ, and can be distinguished by FLIM. This approach has been used to distinguish precancerous lesions from normal tissue [11] , and invasive mammary carcinoma cells from non-invasive cells [8] . Specifically, tumor cells have a higher NADH and FAD fluorescence intensity and a longer fluorescence lifetime than normal cells [11] . Moreover, the fluorescence lifetime for FAD is longer in invasive cells than in cells of the primary tumor mass, suggesting changes that accompany carcinoma progression [8] . Unexpectedly, these fluorophores are preserved in fixed, paraffin-embedded tissue, where the fluorescence intensity and lifetime of NADH and FAD differentiates between tumor and normal mammary epithelium in mouse samples [11] . Thus, application of MPLSM/MPLSM-FLIM to human pathological samples or fresh biopsy tissues may allow the readout of metabolic states, and might help to further differentiate between patient subsets or suggest more targeted therapies. For example, as recently reviewed by Thompson and coworkers [90], the phosphoinositide 3-kinase (PI3K) pathway (including Akt and the tumor suppressor PTEN) important in many human cancers and a target for therapeutic intervention [96] , can regulate cell proliferation and motility as well as glucose metabolism. AKT, a downstream kinase of PI3K, can regulate glucose transporter expression and capture, even in cells that are not insulindependent [90, 97] . Findings such as these suggest that optical detection of changes in fluorescent lifetimes of endogenous fluorophores such as NADH and FAD that report altered glycolysis, could indicate whether therapy targeted against the PI3K pathway is relevant. Moreover, oncogene proteins such as Myc and Ras, and tumor suppressors such as p53, either cause or are sensitive to changes in glucose or glutamine metabolism [90] . Hence, real-time measurement of metabolic state optical biomarkers in single cells could not only provide information regarding transformation or metastatic potential but, particularly when combined with single-cell phenotype data, could be useful for identifying particular oncogenic signaling pathways important in human cancer.
Pathology-associated collagen changes
The deposition of collagen surrounding tumors, termed 'desmoplasia,' has been noted by pathologists over many years, but the functional significance of desmoplasia has only recently been investigated. Importantly, collagen is perhaps the most readily imaged endogenous molecule because fibrillar collagen is a strong harmonophore [48] [49] [50] [51] [52] , and therefore changes in collagen within mammary [15, 98, 99] and ovarian [12] tumors can be detected by SHG.
As described above, the visualization of the collagen matrices surrounding mammary tumors has demonstrated a characteristic sequence in the intensity, organization and alignment of collagen that accompanies tumor progression [15] (Figure 2, Box 3) . These 'tumor-associated collagen signatures,' or TACS, are potentially relevant optical biomarkers and are consistent with the general collagen changes in human breast cancer that are detected by SHG [99] . Because aligned collagen fibers in animal models and in 3D cell culture are associated with (and facilitate) local invasion, these studies link collagen organization to cellular behavior and specific signal transduction pathways, such as Rho/Rock-dependent matrix reorganization [34] . They also suggest that inhibition of intracellular contractility in a non-invasive primary tumor mass might help to block conversion to an invasive tumor. Moreover, locally invasive regions near the tumor mass have a collective migration phenotype, suggesting that contractile and proteolytically active behavior [15, 34, 55, 60, 61] the primary tumor mass can show mesenchymal or amoeboid phenotypes that could depend on the matrix architecture [61] and the mechanism of chemoattraction [37, 69] , and therefore understanding the matrix architecture and the cell phenotype could also direct therapeutic intervention (e.g. amoeboid motility might be targeted as a component of the 'minimum motility pathway'; Refs. [54, 73, 74, 77] ). It is therefore becoming clear that real-time optical imaging of changes in matrix architecture and the corresponding cell behavior in vivo or in situ will be of great utility in cancer biology. Moreover, as our understanding of the molecular basis of invasion into 3D matrices increases, future therapies targeted at these events will hopefully emerge, and would be of particular benefit to patients with an 'invasive' optical biomarker.
The further development of collagen as a biomarker of tumor progression will benefit from additional visualization tools to readily quantify measurements of intensity and alignment, such as algorithms to identify collagen structures in SHG images and color map their angle or scatter properties. In a broader sense, because collagen is the most abundant protein in most vertebrates [100] , collagen has great potential for the depiction of tissue architecture in a wide variety of cell biological, developmental, and pathological investigations in model organisms.
Emerging and future applications
Optical biomarkers including NADH, FAD, and collagen are clearly relevant to carcinoma progression and the signal transduction cascades involved. They are therefore potential read-outs for high-throughput screening. For example, because collagen matrix alignment facilitates invasion [8, 15] , and can be recapitulated in 3D culture [34] , SHG imaging and the analysis of collagen alignment might afford a screening method for small molecules that can prevent this process. Contractility to re-align the matrix is Rho-mediated [34] , and molecules that inhibit the Rho pathway may therefore be effective in preventing carcinoma progression. Similarly, if the tumor-associated switch to glycolysis is recapitulated in cells or tissue explants in culture, then imaging of NADH and FAD may be a useful end-point for screens of small molecules to prevent the switch.
Quantitative techniques and computational tools to standardize and quantify complex datasets from 4D (xy-z-time) imaging [101] will be extremely important for the accurate identification of optical biomarkers associated with disease (see Swedlow and Eliceiri, this issue). Once an optical biomarker (or a consensus panel of biomarkers) is established for a particular human cancer, the link between biomarker and molecular mechanism may be elucidated and, with the appropriate detection technology, analytical tools and drug screens, a personalized tumor phenotype-specific treatment regime may then be in hand. Therefore, the information we gain from optical-imaging studies in animal and culture models of human cancer will not only provide insights into the mechanisms of disease, but also hold great promise for improving disease outcome.
Because of its advantages for tissue imaging, the use of MPLSM as a tool to understand cancer progression in animal models is likely to expand as additional analytical approaches, instrumentation, and expertise become more commonly available. MPLSM has already assisted our understanding of cell invasion and metastasis, and has captured single cells as they invade in vivo. In addition to cancer biology, these imaging approaches are likely to illuminate many normal developmental and pathological processes in vivo. Moreover, MPSLM has great potential as a clinical diagnostic tool (see Box 2), taking advantage of optical biomarkers in fresh tissue biopsies even as a patient is undergoing surgery, or in classic histopathology samples.
